Literature DB >> 28689838

Management of Severe Asthma before Referral to the Severe Asthma Specialist.

Tara F Carr1, Monica Kraft2.   

Abstract

Severe asthma is associated with significant morbidity and can be challenging to assess and control, due to heterogeneity of disease, complexity of diagnosis, and impact of comorbidities. A structured approach to the assessment and management of severe asthma may be helpful to the practicing clinician. First, it is important to confirm a diagnosis of asthma. In patients who are either not responding to treatment, or who require high doses of medication to control symptoms, it is highly possible that disease mimickers or comorbidities are present and can inhibit therapeutic responsiveness. The assessment and management of common comorbidities of asthma may dramatically impact disease control and thus medication requirement. Determining medication adherence and optimizing drug dose and delivery may separate out truly severe asthmatics from those not using medications regularly or properly. Next, although true personalized medicine for severe asthma is not yet realized, for those individuals with severe asthma, phenotypic characteristics of each patient may guide which therapeutic options may be most effective for that patient. Finally, evaluation and management of severe asthma at a referral center can add additional phenotyping, therapeutic, and diagnostic strategies.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adherence; Biologic therapy; Comorbidities; Inhaled corticosteroid; Phenotype; Severe asthma

Mesh:

Substances:

Year:  2017        PMID: 28689838      PMCID: PMC5526085          DOI: 10.1016/j.jaip.2017.04.027

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  99 in total

1.  Pulmonary function characteristics in patients with different patterns of methacholine airway hyperresponsiveness.

Authors:  Annie Lin Parker; F Dennis McCool
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

Review 2.  General considerations for lung function testing.

Authors:  M R Miller; R Crapo; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

Review 3.  Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.

Authors:  C J Cates; J A Crilly; B H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

4.  Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.

Authors:  W W Busse; S Brazinsky; K Jacobson; W Stricker; K Schmitt; J Vanden Burgt; D Donnell; S Hannon; G L Colice
Journal:  J Allergy Clin Immunol       Date:  1999-12       Impact factor: 10.793

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

6.  Use of the forced oscillation technique to assess airway obstruction and reversibility in children.

Authors:  C Delacourt; H Lorino; M Herve-Guillot; P Reinert; A Harf; B Housset
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

7.  Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.

Authors:  Michael R Littner; Felix W Leung; E David Ballard; Bidan Huang; Nina K Samra
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

8.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.

Authors:  Harold S Nelson; Scott T Weiss; Eugene R Bleecker; Steven W Yancey; Paul M Dorinsky
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

9.  Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast.

Authors:  Monica Kraft; Charles B Cairns; Misoo C Ellison; Juno Pak; Charles Irvin; Sally Wenzel
Journal:  Chest       Date:  2006-12       Impact factor: 9.410

10.  Systematic assessment of difficult-to-treat asthma.

Authors:  D S Robinson; D A Campbell; S R Durham; J Pfeffer; P J Barnes; K F Chung
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

View more
  4 in total

Review 1.  Role of Biologics in Asthma.

Authors:  Mary Clare McGregor; James G Krings; Parameswaran Nair; Mario Castro
Journal:  Am J Respir Crit Care Med       Date:  2019-02-15       Impact factor: 21.405

2.  Extracellular Vesicle-Shuttling MicroRNAs Regulate the Development of Inflammatory Lung Responses.

Authors:  Jonathan M Carnino; Kareemah Ni; Yang Jin
Journal:  Ann Pulm Crit Care Med       Date:  2018-12-23

Review 3.  Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments.

Authors:  Laren D Tan; Nolan Nguyen; Abdullah Alismail; Mario Castro
Journal:  J Asthma Allergy       Date:  2022-06-29

4.  Systems Approaches to Treatment Response to Imatinib in Severe Asthma: A Pilot Study.

Authors:  Seung Han Baek; Dinah Foer; Katherine N Cahill; Elliot Israel; Enrico Maiorino; Annika Röhl; Joshua A Boyce; Scott T Weiss
Journal:  J Pers Med       Date:  2021-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.